<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02751034</url>
  </required_header>
  <id_info>
    <org_study_id>MT_PRT_NLF02</org_study_id>
    <nct_id>NCT02751034</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation Study of Neuramis® Deep Lidocaine in Correction of Nasolabial Fold</brief_title>
  <official_title>A Randomized, Multi-center, Double Blind, Intra-Individual Controlled, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Injection With Neuramis® Deep Lidocaine as Compared to Restylane® PERLANE-L in Correction of Nasolabial Fold</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medy-Tox</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medy-Tox</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of the study medical device,
      Neuramis® Deep Lidocaine and the control medical device, Restylane® PERLANE-L in correction
      of nasolabial folds
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center, double blind, intra-individual controlled, active-controlled
      clinical trial.

      Efficacy and Safety are evaluated at the appointed time at subject visit clinical site after
      Injecting medical device.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change on the Wrinkle Severity Rating Scale as evaluated by photograph raters using photographs</measure>
    <time_frame>from baseline to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change on Wrinkle Severity Rating Scale as evaluated by an investigator</measure>
    <time_frame>from baseline to 8, 16, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a ≥ 1 point change on Wrinkle Severity Rating Scale as evaluated by an investigator</measure>
    <time_frame>from baseline to 8, 16, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on Wrinkle Severity Rating Scale as evaluated by photograph raters using photographs</measure>
    <time_frame>from baseline to 8, 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a ≥ 1 point change on Wrinkle Severity Rating Scale as evaluated by photograph raters</measure>
    <time_frame>from baseline to 8, 16, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a ≥ 1 point on Global Aesthetic Improvement Scale as evaluated by an investigator</measure>
    <time_frame>8, 16, 24 weeks after the injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a ≥ 1 point on Global Aesthetic Improvement Scale as evaluated by a subject</measure>
    <time_frame>8, 16, 24 weeks after the injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale as evaluated by a subject</measure>
    <time_frame>at 15, 30, 45, 60 minutes after the injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs, physical examination, laboratory tests and adverse events</measure>
    <time_frame>from baseline to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Nasolabial Fold</condition>
  <arm_group>
    <arm_group_label>Neuramis® Deep Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neuramis® Deep Lidocaine Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restylane® PERLANE-L</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Restylane® PERLANE-L Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neuramis® Deep Lidocaine</intervention_name>
    <description>HA filler</description>
    <arm_group_label>Neuramis® Deep Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane® PERLANE-L</intervention_name>
    <description>HA filler</description>
    <arm_group_label>Restylane® PERLANE-L</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female aged between 30 and 70 years, inclusive

          2. Subjects who want improvement of bilateral nasolabial folds that are rated as 3 or 4
             points on Wrinkle Severity Rating Scale

          3. Subjects with visually symmetrical bilateral nasolabial folds

          4. Subjects who consent to abstain from wrinkle improvement treatment in the lower face
             (below the lower orbital rim) during this trial

          5. Subjects who are capable of understanding and following instructions, and
             participating in the entire course of the trial

          6. Subjects who voluntarily decide to participate in this trial and provide written
             consent in the Informed Consent Form

        Exclusion Criteria:

          1. Subjects who administered an anticoagulant (except for low-dose aspirin (100mg, up to
             300mg/day) or equivalent) within 2 weeks prior to screening

          2. Subjects who had face-lift, soft tissue augmentation, medium or deeper peeling, or
             dermal photo-rejuvenation on the lower face (lower orbital rim) for wrinkle
             improvement within 6 months prior to screening

          3. Subjects who received treatment with calcium hydroxyapatite(CaHA) at the
             investigational medical device injection site within 1 year from screening

          4. Subjects who have implanted a permanent expander prosthesis at the investigational
             medical device injection site, such as soft-form or silicon

          5. Subjects with a scar or skin lesion at the investigational medical device injection
             site that may interfere with judgment of the treatment effect

          6. Subjects with a history of anaphylaxis or severe complicated allergy or allergy to
             lidocaine or hyaluronic acid products

          7. Subjects with a history of a hypertrophic scar or keloid

          8. Subjects with a skin disease or wound infection at the investigational medical device
             injection site

          9. Subjects who participated in another clinical trial within 30 days prior to screening

         10. Pregnant or breastfeeding women or women of childbearing potential who are not using
             medically acceptable contraception or not consenting to practice birth control from
             screening to the end of trial

         11. Subjects who are otherwise determined by the investigator as ineligible for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hoon Kang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University St. Paul Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BeomJoon Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang Univ. Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catholic University St. Paul Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Dongdaemun-gu</state>
        <zip>130-709</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang Univ. Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Dongjak-gu</state>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <last_update_submitted>April 21, 2016</last_update_submitted>
  <last_update_submitted_qc>April 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wrinkle Severity Rating Scale</keyword>
  <keyword>Global Aesthetic Improvement Scale</keyword>
  <keyword>Hyaluronic acid filler</keyword>
  <keyword>filler</keyword>
  <keyword>Nasolabial Fold</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

